Document is current
Any future updates will be listed below
-
Authors
Pierson, Sheila K. https://orcid.org/0000-0002-3736-1411
Katz, Laura
Williams, Reece
Mumau, Melanie https://orcid.org/0000-0003-2145-8347
Gonzalez, Michael
Guzman, Stacy https://orcid.org/0000-0003-0713-0652
Rubenstein, Ayelet
Oromendia, Ana B.
Beineke, Philip
Fosså, Alexander
van Rhee, Frits https://orcid.org/0000-0001-9959-1282
Fajgenbaum, David C. https://orcid.org/0000-0002-7367-8184
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL141408)
Janssen Research and Development
Castleman Disease Collaborative Network
- License Information
-
More Information
Article History
Received: 12 January 2022
Accepted: 10 November 2022
First Online: 24 November 2022
Competing interests
: D.C.F. has received research funding for the ACCELERATE registry from EUSA Pharma and consulting fees from EUSA Pharma, and Pfizer provides a study drug with no associated research funding for the clinical trial of sirolimus (NCT03933904). D.C.F. has two provisional patents pending related to the diagnosis and treatment of iMCD, including one related to CXCL13 as a biomarker in iMCD. A.B.O., L.K., and P.B. are employed by and/or receive equity ownership from Medidata Solutions, a subsidiary of 3DS. A.F. has received honoraria and research support from Janssen Pharmaceuticals and EUSA Pharma. F.v.R. provides consultancy for EUSA Pharma, Takeda, Sanofi Genzyme, Adicet Bio, Kite Pharma, and Karyopharm Therapeutics. The remaining authors declare no competing interests.
